Nanomedicine for the Treatment of Lungs Cancer Its Challenges and Future Perspective-A Review
Main Article Content
Abstract
A major public health concern with a global reach,lungs cancer necessitates cutting-edge techniques to treatment. Nanomedicine is a new technology that is currently being used to treat and diagnose lung cancer. This review examines the difficulties in using nano medicine to treat lung cancer and shows the promising directions for this rapidly developing field of study. The issues raised in this review cover a wide range of topics, such as medication delivery, targeted precision, toxicity, and legal obstacles. Approaches based on nanomedicine have the potential to get through these barriers thanks to improvements in drug delivery to lung cancer cell, a decrease in side effects, and increased therapeutic effectiveness. Additionally, this study explores the potential applications of nanomedicine for the treatment of lung cancer, highlighting the significance of cutting-edge technology including personalized medicine techniques,theranostic nanosystems, and targeted nanoparticles. These developments carry the possibility of individualized treatment plans, improved therapeutic results, and reduced side effects.
Nanomedicine offers a multifaceted approach to address the challenges of lung cancer treatment, bringing new hope to patients and clinicians alike. By overcoming existing limitations and harnessing the potential of emerging technologies, nano medicine is poised to play a pivotal role in the future of lung cancer therapy. This review serves as a comprehensive overview of the field, shedding light on the path forward in the fight against lung cancer.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Bade, B. C., and Dela Cruz, C. S. (2020). Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 41 (1), 1–24. doi:10.1016/j.ccm.2019.10.001
Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61(2):91–112
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E (2013) European cancer mortality predictions for the year 2013. Ann Oncol 24(3):792–800
Yano T, Okamoto T, Fukuyama S, Maehara Y (2014) Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol 5(5):1048–1054
Strebhardt K, Ullrich A. 2008. Paul ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8: 473–480
Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56: 1649–1659.
.Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M. 2004. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 10: 2168–2178
Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. International reviews of immunology. 2007 Jan 1;26(3-4):223-47.
Huang A, Huang L, Kennel SJ. 1980. Monoclonal-antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting. J. Biol. Chem. 255: 8015–8018.
Cardoso MM, Peca IN, Roque AC. 2012. Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem. 19: 3103–3127.
Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata KI, Kikuchi H, Akita H, Asai T. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biological and Pharmaceutical Bulletin. 2007;30(5):972-8.
Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. 2002. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591: 109–118.
Ross JF, Chaudhuri PK, Ratnam M. 1994. Differential regulation of folate receptor isoforms in normal and malignant-tissues in vivo and in established cell-lines. Physiological and clinical implications. Cancer 73: 2432–2443.
Pegram MD, Konecny G, Slamon DJ. 2000. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. In Advances in Breast Cancer Management, Gradishar WJ, Wood WC (eds). Springer Science: New York; 103: 57–75.
Khemtong C, Kessinger CW, Ren J, Bey EA, Yang SG, Guthi JS, Boothman DA, Sherry AD, Gao J. 2009. In vivo off-resonance saturation magnetic resonance imaging of ????v????3-targeted superparamagnetic nanoparticles. Cancer Res. 69: 1651–1658.
Iyer AK, Khaled G, Fang J, Maeda H. 2006. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11: 812–818
Risau W. 1997. Mechanisms of angiogenesis. Nature 386: 671–674.
Shubik P. 1982. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol. 103: 211–226
Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303(5665):1818–1822
Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U (2007) Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 6(11):3019–3027
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4(2):145–160
Landesman-Milo D, Peer D (2012) Altering the immune response with lipid-based nanoparticles. J Control Release 161(2):600–608
Landesman-Milo D, Ramishetti S, Peer D (2015) Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev 34(2):291–301
Zhu L, Ma J, Jia N, Zhao Y, Shen H. Chitosan-coated magnetic nanoparticles as carriers of 5-fuorouracil: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces. 2009;68(1):1–6.
Lin AY, Young JK, Nixon AV, Drezek RA. Encapsulated Fe3O4/Ag complexed cores in hollow gold nanoshells for enhanced theranostic magnetic resonance imaging and photothermal therapy. Small. 2014;10(16):3246–51.
Lin H, Chen Y, Shi J. Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specifc therapy. Chem Soc Rev. 2018;47(6):1938–58.
Han Y, Gao S, Zhang Y, Ni Q, Li Z, Liang XJ, Zhang J. Metal-based nanocatalyst for combined cancer therapeutics. Bioconjug Chem. 2020;31(5):1247–58.
Liu Y, Zhen W, Wang Y, Liu J, Jin L, Zhang T, Zhang S, Zhao Y, Song S, Li C, Zhu J, Yang Y, Zhang H. One-dimensional Fe(2) P acts as a Fenton agent in response to NIR II light and ultrasound for deep tumor synergetic theranostics. Angew Chem Int Ed Engl. 2019;58(8):2407–12.
Eshaghi Malekshah R, Fahimirad B, Khaleghian A. Synthesis, characterization, biomedical application, molecular dynamic simulation and molecular docking of schif base complex of Cu(II) supported on Fe(3)O(4)/SiO(2)/APTS. Int J Nanomed. 2020;15:2583–603
Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–7
Yang Z, Sun Z, Ren Y, Chen X, Zhang W, Zhu X, Mao Z, Shen J, Nie S. Advances in nanomaterials for use in photothermal and photodynamic therapeutics (Review). Mol Med Rep. 2019;20(1):5–15.
Attarilar S, Yang J, Ebrahimi M, Wang Q, Liu J, Tang Y, Yang J. The toxicity phenomenon and the related occurrence in metal and metal oxide nanoparticles: a brief review from the biomedical perspective. Front Bioeng Biotechnol. 2020;8:822
Abu Lila AS, Ishida T. Liposomal Delivery Systems:Design Optimization and Current Applications. Biol Pharm Bul Biol Pharm Bull. 2017;40:1–10. [PubMed] [Google Scholar]
Haluska CK, Riske KA, Marchi-Artzner V, Lehn JM, Lipowsky R, Dimova R. Time Scales of Membrane Fusion Revealed by Direct Imaging of Vesicle Fusion with High Temporal Resolution. Proc Natl Acad Sci. 2006;103:15841–6. [PMC free article] [PubMed] [Google Scholar]
Torchilin VP. Recent Advances with Liposomes as Pharmaceutical Carriers. Nat Rev Drug Discov. 2005;4:145–60. [PubMed] [Google Scholar].
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final Overall Survival Results of Phase III GCIG CALYPSO Trial of Pegylated Liposomal Doxorubicin and Carboplatin vs Paclitaxel and Carboplatin in Platinum-sensitive Ovarian Cancer Patients. Br J Cancer. 2012;107:588–91. [PMC free article] [PubMed] [Google Scholar].
Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid Lipid Nanoparticles:A Review on Recent Perspectives and Patents. Expert Opin Ther Pat. 2020;30:179–94. [PubMed] [Google Scholar].
Aupérin A, Péchoux CL, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2010;28:2181–90. [PubMed] [Google Scholar].
Hamroun A, Lenain R, Bigna JJ, Speyer E, Bui L, Chamley P, et al. Prevention of Cisplatin-induced Acute Kidney Injury:A Systematic Review and Meta-analysis. Drugs. 2019;79:1567–82. [PubMed] [Google Scholar].
Boulikas T. Clinical Overview on Lipoplatin™:A Successful Liposomal Formulation of Cisplatin. Expert Opin Investig Drugs. 2009;18:1197–218. [PubMed] [Google Scholar].
Giuberti CD, Reis EC, Rocha TG, Leite EA, Lacerda RG, Ramaldes GA, et al. Study of the Pilot Production Process of Long-Circulating and pH-sensitive Liposomes Containing Cisplatin. J Liposome Res. 2010;21:60–9. [PubMed] [Google Scholar].
Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of Liposomal Cisplatin Versus Cisplatin in Non-squamous Cell Non-small-cell Lung Cancer. Cancer Chemother Pharmacol. 2011;68:945–50. [PMC free article] [PubMed] [Google Scholar].
Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of Liposomal Cisplatin Versus Cisplatin in Non-squamous Cell Non-small-cell Lung Cancer. Cancer Chemother Pharmacol. 2011;68:945–50. [PMC free article] [PubMed] [Google Scholar].
Baker JR Jr. Dendrimer-based nanoparticles for cancer therapy. Hematol Am Soc Hematol Educ Program. 2009;209:708–19.
Li D, Fan Y, Shen M, Bányai I, Shi X. Design of dual drug-loaded dendrimer/carbon dot nanohybrids for fuorescence imaging and enhanced chemotherapy of cancer cells. J Mater Chem B. 2019;7(2):277–85.
Pishavar E, Ramezani M, Hashemi M. Co-delivery of doxorubicin and TRAIL plasmid by modifed PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2019;45(12):1931–9.
Tarach P, Janaszewska A. Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy. Int J Mol Sci. 2021;22(6):2912.
Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123–7.
Sharma N, Bansal M, Visht S, Sharma PK, Kulkarni GT. Nanoemulsion: A new concept of delivery system. Chronicles of Young Scientists. 2010 Apr 1;1(2):2-6.
.Gorain B, Choudhury H, Nair AB, Dubey SK, Kesharwani P. Theranostic application of nanoemulsions in chemotherapy. Drug Discov Today. 2020;25(7):1174–88.
Du M, Yang Z, Lu W, Wang B, Wang Q, Chen Z, Chen L, Han S, Cai T, Cai Y. Design and development of spirulina polysaccharide-loaded nanoemulsions with improved the antitumor efects of paclitaxel. J Microencapsul. 2020;37(6):403–12
Dianzani C, Monge C, Miglio G, Serpe L, Martina K, Cangemi L, Ferraris C, Mioletti S, Osella S, Gigliotti CL, Boggio E, Clemente N, Dianzani U, Battaglia L. Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment. Cancers (Basel). 2020;12(5):1198